News
Feed
Events
Feed
News
+ Events
Feed

Secarna Pharmaceuticals GmbH & Co. KG

  • Land Deutschland

Aktuelle News

20 März 2024

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

3 November 2023

18:05 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

25 Oktober 2023

15:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

17 Oktober 2023

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society

6 Juli 2023

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

5 Juni 2023

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

27 März 2023

16:04 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

31 Mai 2022

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

12 April 2022

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

22 Februar 2022

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

10 November 2021

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

26 Oktober 2021

15:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

25 Oktober 2021

15:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs

5 Oktober 2021

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus(TM)-based ASOs to effectively treat diabetic kidney disease

2 September 2021

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

5 August 2021

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

4 Februar 2021

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director

20 Januar 2021

15:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies

19 Januar 2021

15:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

8 Dezember 2020

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Data published in Cancer Research show Secarna Pharmaceuticals’ LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of colorectal and lung cancers in vivo

13 Oktober 2020

17:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases

5 August 2020

07:30 Corporate

Secarna Pharmaceuticals GmbH & Co. KG

Corporate

Secarna Pharmaceuticals und Evotec gehen strategische Partnerschaft im Bereich Antisense-Therapie ein

28 April 2020

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections

26 März 2020

08:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals’ LNA-modified ASOs to effectively block important immunosuppressive pathway

23 März 2020

08:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

11 November 2019

09:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals successfully completes financing round

7 November 2019

14:20 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals to Attend International Partnering and Investor Conferences in November

10 September 2019

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals enters into oncology research agreement with global top 10 pharmaceutical company

6 Mai 2019

14:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Publications of Secarna Pharmaceuticals’ immuno-oncology data in peer-reviewed scientific journals support potential of LNAplusTM antisense oligonucleotide platform for discovering novel cancer therapies

5 November 2018

11:00 Corporate EN

Secarna Pharmaceuticals GmbH & Co. KG

Corporate
EN

Secarna Pharmaceuticals and MetP Pharma enter into a co-development agreement for transnasally delivered antisense oligonucleotide-based CNS therapeutics

Anstehende Events

Keine Events gefunden